Large-scale testing (Phase 3)Active Not RecruitingNCT07220109
What this trial is testing
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
Who this might be right for
Respiratory Syncytial Virus Infections
GlaxoSmithKline 750